Retatrutide Manufacturer/2381089-83-2/Peptide supplier

Description

Retatrutide is an experimental drug used to treat obesity. It is a novel triple receptor agonist targeting glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. In Phase 2 clinical trials, it has been shown to reduce the average body weight of adults who are obese or overweight (pre-obese) but not diabetic by more than 17.5%.

Specifications

Apperance: White to off-white powder

Purity(HPLC): ≥98.0%

Single Impurity: ≤2.0%

Acetate Content(HPLC): 5.0%～12.0%

Water Content (Karl Fischer): ≤10.0%

Peptide Content: ≥80.0%

Packing and Shipping: Low temperature, vacuum packing, accurate to mg as required.

FAQ：

What is Net Peptide Content?
It is important to understand the difference between net peptide content and total peptide weight (gross weight). In general, peptide lyophilized powder samples contain not only peptides, but also other substances such as water, solvents absorbed by peptides, counterions, and salts. The total peptide weight (gross weight) refers to the weight of all these mixtures. The net peptide content is relative to the non-peptide substances, balanced ions and water, and after removing these, the remaining is the net peptide content. The net peptide content can be determined by nitrogen analysis or amino acid composition analysis, usually accounting for 50-80% of the total peptide weight. Net peptide content is different from peptide purity, which refers to the percentage of peptide of interest in a sample.

What are the applications of peptide libraries?
Peptide libraries are an efficient tool for many studies, including GPCR ligand screening, protein-protein interaction studies, functional proteomics, nucleotide binding, screening of enzymatically acting substrates and inhibitors, antigen and epitope screening, signaling molecule search, and other important processes of drug screening.

What are small molecular peptides?

Peptides are formed by multiple amino acids connected through peptide bonds. The difference from proteins is the number of amino acids that make up the molecule. Oligopeptides, consisting of 2-9 amino acids, are also known as small molecular peptides, with an average molecular weight of amino acids being 128 Da. Therefore, the molecular weight of oligopeptides is generally less than 1000 Da.

What are the advantages of Pharmaceutical Peptide?
The rapid development of Pharmaceutical Peptide benefits from their significant advantages:

• Significant activity, relatively strong specificity, good affinity for receptors, lower toxicity, and not easily accumulating in the body;

 • Compared to protein-based macromolecular drugs, except for peptide vaccines, peptide drugs have relatively low immunogenicity, require smaller dosages, and have higher unit activity;

 • Easy to modify and produce, and can even be addressed through synthetic methods.

Why should peptides be modified by N-terminal acetylation and C-terminal amidation?
Such modifications can give peptide sequences properties that are native to proteins.